Skyrizi

1 trends tracked about this subject — the full history, oldest to newest below.

▲ Peaking Business

AbbVie's experimental dual-targeting therapy ABBV-466 shows higher endoscopic remission rates in a phase 2 trial for Crohn's disease.

5 sources 5 articles v 3 16h ago

\n \n \n

\n \n \n \n